Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous inactivated whole HIV-1 pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Hospital Clínic de Barcelona
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
The autologous inactivated whole HIV-1 pulsed dendritic cell vaccine is an investigational cell-based therapeutic vaccine designed to treat chronic HIV-1 infection. The vaccine is produced by isolating monocyte-derived dendritic cells (MD-DCs) from an HIV-infected individual and pulsing them ex vivo with the patient's own (autologous) HIV-1 that has been heat-inactivated. This personalized approach aims to present the full spectrum of the individual's viral antigens to their immune system. Once re-administered, these mature dendritic cells act as potent antigen-presenting cells, stimulating HIV-specific CD4+ and CD8+ T-cell responses to improve viral control. Clinical trials, such as the DCV-2 study (NCT00402142) led by researchers at the Hospital Clínic de Barcelona, have demonstrated that the vaccine can induce a significant, albeit modest, reduction in plasma viral load during analytical treatment interruption.
- Other names
- autologous monocyte-derived dendritic cells pulsed with heat inactivated autologous HIV-1Barcelona HIV vaccineDCV-2 vaccineDCV2 vaccineDCV 2 vaccineMD-DC pulsed with heat-inactivated autologous HIV-1
Beyond the preview
Go deeper on autologous inactivated whole HIV-1 pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous inactivated whole HIV-1 pulsed dendritic cell vaccine.